Rebecca Porter

4PUBLICATIONS
29CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Mar 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.

Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir

|Dec 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

Rebecca Porter, Bruno Bockorny, Bradley R Corr

|Jul 12, 2024
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.

Mubin Tarannum, Khanhlinh Dinh, Juliana Vergara

|Sep 16, 2021
Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.

Rebecca L Porter, Ursula A Matulonis

Pageof 1

Frequent Collaborators

1 joint publications

Ursula A Matulonis

1 joint publications

Mubin Tarannum

1 joint publications

Khanhlinh Dinh

1 joint publications

Juliana Vergara